Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 11—November 2005


Neutralizing Antibody Response and SARS Severity

Mei-Shang Ho*, Wei-Ju Chen*, Hour-Young Chen†, Szu-Fong Lin†, Min-Chin Wang†, Jiali Di†, Yen-Ta Lu‡, Ching-Lung Liu‡, Shan-Chwen Chang§, Chung-Liang Chao¶, Chwan-Chuen King§, Jeng-Min Chiou*, Ih-Jen Su#, and Jyh-Yuan Yang†Comments to Author 
Author affiliations: *Academia Sinica, Taipei, Taiwan; †Center for Disease Control, Taipei, Taiwan; ‡Taipei Mackay Memorial Hospital, Taipei, Taiwan; §National Taiwan University, Taipei, Taiwan; ¶Taipei Hospital, Taipei, Taiwan; #National Health Research Institutes, Taipei, Taiwan

Main Article

Table 6

Comparison of early seroresponders and other SARS patients, by death rate, time of death, and age*

Factor Early seroresponders†
OR p value‡
Yes, n (%) No, n (%)
Yes 29.6 (8) 7.8 (10) 4.97 0.004
No 70.4 (19) 92.2 (118) 1.00
Died within 2 wk
Yes 75.0 (6) 10.0 (1) 0.013
No 25.0 (2) 90.0 (9)
Age (y)
>60 (n = 14) 42.9 (6) 57.1 (8) 0.01
<60 (n = 141) 14.9 (21) 85.1 (120)

*SARS, severe acute respiratory syndrome; OR, odds ratio.
†Early seroresponders are SARS patients who were seropositive for SARS neutralizing antibody during the first 2 weeks of illness.
‡p value based on Fisher exact test.

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO